RAC1 and cancer: Our additional findings on the in vivo Rac1 inhibitor sensitivity in RAC1-amp melanoma and RAC1-A159V-mutated endometrial cancer, and the noted outlier EHT-1864 sensitivity (inhibitor of Rac1, Rac2, and Rac3) from the GDSC dataset both suggest that the chemical targeting of Rac1 or Rac1, 2, or 3 may be worth more attention in other cancers, such as ECAD, stomach, ALL, breast, LUAD (based on GDSC data), and endometrial cancers, as well as melanoma (based on our findings).